{"filings":[{"id":94497,"accession_number":"0001493152-26-019485","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["8.01","2.02","2.01","7.01","9.01"],"status":"ready","headline":"enVVeno receives FDA IDE approval for pivotal study of non-surgical venous valve; $25M cash","event_type":"regulatory","confidence":"high","bullets":["FDA grants first-ever IDE for a U.S. pivotal study of a non-surgical replacement venous valve (enVVe System).","TAVVE study: stage 1 enrolls 10 patients; stage 2 enrolls 220 patients (165 valve, 55 control) at up to 40 US sites.","Company reports ~$25M cash/investments as of March 31, 2026, funding operations into Q3 2027.","Addresses ~3 million U.S. patients with severe deep CVI; no effective current treatments for valvular incompetence.","enVVe features: 13Fr delivery profile, porcine pericardium leaflet, no general anesthesia needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106923,"accession_number":"0001493152-26-005030","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"enVVeno Medical regains Nasdaq minimum bid price compliance; reports $28M cash at year-end","event_type":"regulatory","confidence":"high","bullets":["Received formal Nasdaq notice confirming compliance with minimum bid price rule; closing bid ≥ $1.00 for 10 consecutive business days Jan 20 - Feb 2, 2026, matter closed.","Cash and investments balance approximately $28 million as of December 31, 2025.","Company expects to share additional details on 2026 strategic plans in coming weeks; believes it is well-positioned for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106922,"accession_number":"0001493152-26-002860","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"enVVeno Medical effects 1:35 reverse stock split, shares outstanding drop to ~655,606","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1:35 effective Jan 20, 2026; no fractional shares issued, rounded up.","Outstanding shares reduced from 22,946,223 to 655,606; authorized shares unchanged at 250M.","Proportional adjustments made to stock options and warrants (e.g., exercise price increased 35x).","Common stock began trading on split-adjusted basis Jan 20, 2026; transfer agent Equiniti managing exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123248,"accession_number":"0001493152-25-027482","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"enVVeno stockholders reject 2025 equity plan; authorize reverse stock split","event_type":"other_material","confidence":"high","bullets":["Elected Jenusaitis (3.47M for, 1.80M withheld) and Berman (4.73M for, 0.54M withheld) as Class II directors.","Advisory say-on-pay passed: 3.19M for, 1.96M against, 5.79M broker non-votes.","Stockholders voted AGAINST the 2025 Equity Incentive Plan (2.48M for, 2.62M against); 2016 plan remains.","Approved reverse stock split authorization (7.31M for, 1.58M against) at ratio of 1:5 to 1:35 at Board discretion.","Ratified CBIZ CPAs P.C. as auditor for FY2025 (10.86M for, 0.14M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123247,"accession_number":"0001493152-25-024494","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"enVVeno Medical lowers stockholder meeting quorum to 33-1/3% voting power","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to Section 1.5 of Amended and Restated Bylaws on November 17, 2025.","New quorum threshold: presence of holders of 33⅓% of voting power of outstanding shares entitled to vote.","Amendment effective immediately upon Board approval; no stockholder vote required.","Change modifies quorum requirement from the prior standard (not specified) to one-third threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123246,"accession_number":"0001493152-25-022440","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"enVVeno loses FDA appeal for VenoValve PMA; shifts focus to enVVe device","event_type":"regulatory","confidence":"high","bullets":["Unfavorable FDA appeal upheld not-approvable letter for VenoValve (received Aug 19, 2025).","Company to redirect resources to next-gen transcatheter valve enVVe, ready for human testing.","Cash and investments totaled $31.5M at Q3 end; quarterly burn $4-5M funds operations into 2027.","No approved treatments exist for severe deep CVI from valvular incompetence, affecting up to 3.5M US patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123245,"accession_number":"0001493152-25-020276","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"enVVeno Medical enters ATM offering agreement for up to $50M of common stock","event_type":"other_material","confidence":"high","bullets":["Agreement with Ladenburg Thalmann allows sale of up to $50M of common stock from time to time.","Shares sold at market prices; agent receives 3% commission on gross proceeds.","ATM shares issued under existing effective S-3 registration statement (filed Aug 23, 2023).","Company has no obligation to sell shares; may suspend or terminate the program at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123244,"accession_number":"0001493152-25-017691","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"enVVeno Medical receives Nasdaq bid-price deficiency notice; cure period to April 2026","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified enVVeno on Oct 7, 2025 that bid price closed below $1.00 for 30 consecutive business days.","Company has until April 6, 2026 to regain compliance by closing at or above $1.00 for 10 consecutive trading days.","If unmet, may seek 180-day extension by meeting other listing standards and committing to reverse stock split.","No immediate effect on listing; stock remains on Nasdaq Capital Market pending cure or appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139926,"accession_number":"0001493152-25-012181","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"enVVeno receives FDA not-approvable letter for VenoValve PMA","event_type":"regulatory","confidence":"high","bullets":["FDA issued not-approvable letter for VenoValve PMA, citing insufficient benefit-risk profile.","FDA raised concerns about bias without hemodynamic measurement and safety from open surgical procedure.","Company reviewing options including resubmission or appeal; continues to work with FDA.","VenoValve is lead product for severe deep chronic venous insufficiency; no approved effective treatments currently.","Company also developing non-surgical enVVe valve; expects to apply learnings for its IDE application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157527,"accession_number":"0001641172-25-011729","cik":1661053,"company_name":"enVVeno Medical Corp","ticker":"NVNO","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"enVVeno Medical appoints Jennifer Bright as CFO, replacing Craig Glynn","event_type":"leadership","confidence":"high","bullets":["Craig Glynn resigned as CFO effective May 19, 2025; will serve as consultant for transition.","Jennifer Bright appointed CFO; 25+ yr CPA, ex-CFO of BIOLASE, salary $300K, bonus up to 40%.","Bright awarded 350,000 stock options at $3.62/share, vesting over 3 years with 1-year cliff.","No disagreement with Glynn; standard employment and indemnification agreements signed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}